Apinocaltamide
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2020 (NCT04625101)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Voltage-gated T-type calcium channel blocker
- Voltage-gated T-type calcium channelINHIBITOR
Voltage-gated T-type calcium channel inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N#Cc1ccc(Cn2ccc(NC(=O)Cc3ccc(C4(C(F)(F)F)CC4)cc3)n2)nc1- Mol. weight
- 425.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4217292 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05301894 | Phase 2 | Jun 7, 2022 | Neurocrine Biosciences |
| NCT04880616 | Phase 2 | Apr 20, 2021 | Neurocrine Biosciences |
| NCT04625101 | Phase 2 | Nov 30, 2020 | Neurocrine Biosciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neurocrine Biosciences | For profit | 3 | 3 | 1 | 2020 |
1 organizations
Page 1 / 1